Take Temozar capsules orally once daily, on an empty stomach (at least one hour before or two hours after food). Capsules should be swallowed whole with a glass of water and not opened, chewed, or crushed. Taking the dose at bedtime may help reduce nausea and vomiting.

Temozolomide is an imidazotetrazine derivative which undergoes rapid chemical conversion at physiological pH to the active compound monomethyl triazenoimidazole carboxamide (MTIC). MTIC alkylates DNA, primarily at the N7-guanine and O6-guanine positions, leading to DNA damage, cell cycle arrest, and apoptosis in rapidly dividing cancer cells.

• •Hypersensitivity to temozolomide or dacarbazine (since MTIC is the active metabolite of dacarbazine).
• •Severe myelosuppression (e.g., severe thrombocytopenia, leukopenia) before starting treatment.

Store at room temperature (below 30°C), protected from light and moisture. Keep out of reach of children.

Overdose is likely to result in increased myelosuppression. Treatment for overdose should consist of symptomatic and supportive therapy, including regular monitoring of blood counts and appropriate interventions if severe myelosuppression occurs.

Pregnancy Category D: Temozolomide can cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant. Lactation: It is unknown whether temozolomide is excreted in human milk. Because of the potential for serious adverse reactions in breastfed infants, women should not breastfeed during treatment.